EA202090945A1 - Анти-msln-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его - Google Patents

Анти-msln-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его

Info

Publication number
EA202090945A1
EA202090945A1 EA202090945A EA202090945A EA202090945A1 EA 202090945 A1 EA202090945 A1 EA 202090945A1 EA 202090945 A EA202090945 A EA 202090945A EA 202090945 A EA202090945 A EA 202090945A EA 202090945 A1 EA202090945 A1 EA 202090945A1
Authority
EA
Eurasian Patent Office
Prior art keywords
msln
treatment
antibody
pharmaceutical composition
oncological diseases
Prior art date
Application number
EA202090945A
Other languages
English (en)
Inventor
Ки Су Ким
Дзун Хонг Дзеонг
Донг Сик Ким
Янг Ми Лим
Йонг Йеа Парк
Хиунг Квон Лим
Дзонг Вха Вон
Original Assignee
Грин Кросс Корпорейшн
Могам Инститьют Фор Байомедикал Рисерч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Грин Кросс Корпорейшн, Могам Инститьют Фор Байомедикал Рисерч filed Critical Грин Кросс Корпорейшн
Publication of EA202090945A1 publication Critical patent/EA202090945A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к анти-MSLN-антителу и фармацевтической композиции для лечения онкологического заболевания, содержащей его. Анти-MSLN-антитело по настоящему изобретению обладает высокой аффинностью и специфичностью к MSLN и, таким образом, может быть эффективно использовано для профилактики или лечения онкологического заболевания.
EA202090945A 2017-10-20 2018-10-22 Анти-msln-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его EA202090945A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170136565A KR101966362B1 (ko) 2017-10-20 2017-10-20 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
PCT/KR2018/012493 WO2019078698A2 (ko) 2017-10-20 2018-10-22 항 -msln항체 및 이를포함하는 암치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
EA202090945A1 true EA202090945A1 (ru) 2020-07-14

Family

ID=66103738

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090945A EA202090945A1 (ru) 2017-10-20 2018-10-22 Анти-msln-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его

Country Status (14)

Country Link
US (1) US11401343B2 (ru)
EP (1) EP3699199A4 (ru)
JP (1) JP6978598B2 (ru)
KR (1) KR101966362B1 (ru)
CN (1) CN111247173B (ru)
AU (1) AU2018351417B2 (ru)
BR (1) BR112020007739A2 (ru)
CA (1) CA3077009C (ru)
EA (1) EA202090945A1 (ru)
IL (1) IL274008A (ru)
MX (1) MX2020003943A (ru)
MY (1) MY194272A (ru)
SG (1) SG11202003278RA (ru)
WO (1) WO2019078698A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202192654A1 (ru) * 2019-03-29 2021-12-30 Грин Кросс Корпорейшн Слитый белок, содержащий анти-мезотелин антитело, анти-cd3 антитело или анти-egfr антитело, биспецифическое или триспецифическое антитело, содержащие его, и их применения
WO2022242703A1 (zh) * 2021-05-19 2022-11-24 江苏先声药业有限公司 抗msln抗体及其应用
WO2023131276A1 (zh) * 2022-01-06 2023-07-13 原启生物科技(上海)有限责任公司 靶向msln的抗原结合蛋白及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PL2195017T3 (pl) 2007-10-01 2015-03-31 Bristol Myers Squibb Co Ludzkie antyciała, które wiążą mezotelinę i ich zastosowania
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
KR101108642B1 (ko) * 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
AU2013324049B2 (en) * 2012-09-27 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
AU2016312015A1 (en) 2015-08-21 2018-04-12 Crage Medical Co., Limited Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
KR101782487B1 (ko) 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 신규 항-메소텔린 항체 및 이를 포함하는 조성물

Also Published As

Publication number Publication date
IL274008A (en) 2020-05-31
SG11202003278RA (en) 2020-05-28
US11401343B2 (en) 2022-08-02
CN111247173B (zh) 2024-03-29
EP3699199A4 (en) 2021-06-30
JP6978598B2 (ja) 2021-12-08
MX2020003943A (es) 2020-08-13
AU2018351417B2 (en) 2021-12-23
EP3699199A2 (en) 2020-08-26
JP2021507678A (ja) 2021-02-25
KR101966362B1 (ko) 2019-04-05
MY194272A (en) 2022-11-25
CN111247173A (zh) 2020-06-05
AU2018351417A1 (en) 2020-05-28
CA3077009C (en) 2023-05-16
BR112020007739A2 (pt) 2020-10-20
CA3077009A1 (en) 2019-04-25
WO2019078698A2 (ko) 2019-04-25
US20200262928A1 (en) 2020-08-20
WO2019078698A3 (ko) 2019-07-04

Similar Documents

Publication Publication Date Title
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201690306A1 (ru) Ингибиторы ido
EA201591599A1 (ru) Ингибиторы ido
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201690027A1 (ru) Ингибиторы ido
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201792231A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201790998A1 (ru) Иммуннорегуляторные агенты
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
EA201800444A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
EA201690152A1 (ru) Ингибиторы ido
EA201591823A1 (ru) Ингибиторы ido
EA201792229A1 (ru) Ингибиторы бромодомена
EA201791775A1 (ru) Цистеиновая протеаза
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
EA201992595A1 (ru) Усиление фармакокинетики бифункциональных хелатов и их применения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201792580A1 (ru) Ингибиторы ido